nach oben

Child's Nervous System

Erschienen in:

03.07.2020 | Annual issue paper

An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains

verfasst von: Taylor F. Smith, Jessica A. Kaczorowski, Maria T. Acosta

Erschienen in: Child's Nervous System | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Neurofibromatosis type 1 (NF1) is a rare monogenic disorder associated with executive function (EF) deficits and heightened risk for attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The goal of this paper is to understand how EFs provide a common foundation to understand vulnerabilities for ADHD and ASD within NF1.

Methods

A literature review and synthesis was conducted.

Results

EF difficulties in working memory, inhibitory control, cognitive flexibility, and planning are evident in NF1, ADHD, and ASD. However, relatively little is known about the heterogeneity of EFs and ADHD and ASD outcomes in NF1. Assessment of ADHD and ASD in NF1 is based on behavioral symptoms without understanding neurobiological contributions. Recent efforts are promoting the use of dimensional and multidisciplinary methods to better understand normal and abnormal behavior, including integrating information from genetics to self-report measures.

Conclusion

NF1 is a monogenic disease with well-developed molecular and phenotypic research as well as complementary animal models. NF1 presents an excellent opportunity to advance our understanding of the neurobiological impact of known pathogenic variation in normal and abnormal neural pathways implicated in human psychopathology. EFs are core features of NF1, ADHD, and ASD, and these neurodevelopmental outcomes are highly prevalent in NF1. We propose a multilevel approach for understanding EFs in patients with NF1.This is essential to advance targeted interventions for NF1 patients and to advance the exciting field of research in this condition.

Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332. https://doi.org/10.1002/ajmg.a.33139CrossRefPubMed

Neurofibromatosis (1987) Natl inst health consens dev conf consens statement, vol 6, pp 1–7

Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primers 3:17004. https://doi.org/10.1038/nrdp.2017.4CrossRefPubMed

Kaczorowski JA, Smith TF, Shrewsbury AM, Thomas LR, Knopik VS, Acosta MT (2020) Neurofibromatosis type 1 implicates Ras pathways in the genetic architecture of neurodevelopmental disorders. Behav Genet. https://doi.org/10.1007/s10519-020-09991-x

Selumetinib Shrinks Tumors in Neurofibromatosis (2020) Cancer Discov. https://doi.org/10.1158/2159-8290.CD-NB2020-025

Uthoff J, Larson J, Sato TS, Hammond E, Schroeder KE, Rohret F, Rogers CS, Quelle DE, Darbro BW, Khanna R, Weimer JM, Meyerholz DK, Sieren JC (2020) Longitudinal phenotype development in a minipig model of neurofibromatosis type 1. Sci Rep 10:5046. https://doi.org/10.1038/s41598-020-61251-4CrossRefPubMedPubMedCentral

White KA, Swier VJ, Cain JT, Kohlmeyer JL, Meyerholz DK, Tanas MR, Uthoff J, Hammond E, Li H, Rohret FA, Goeken A, Chan CH, Leidinger MR, Umesalma S, Wallace MR, Dodd RD, Panzer K, Tang AH, Darbro BW, Moutal A, Cai S, Li W, Bellampalli SS, Khanna R, Rogers CS, Sieren JC, Quelle DE, Weimer JM (2018) A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI Insight 3. https://doi.org/10.1172/jci.insight.120402

Acosta MT, Bearden CE, Castellanos FX, Cutting L, Elgersma Y, Gioia G, Gutmann DH, Lee YS, Legius E, Muenke M, North K, Parada LF, Ratner N, Hunter-Schaedle K, Silva AJ (2012) The learning disabilities network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am J Med Genet A 158A:2225–2232. https://doi.org/10.1002/ajmg.a.35535CrossRefPubMed

Torres Nupan MM, Velez Van Meerbeke A, Lopez Cabra CA, Herrera Gomez PM (2017) Cognitive and behavioral disorders in children with neurofibromatosis type 1. Front Pediatr 5:227. https://doi.org/10.3389/fped.2017.00227CrossRefPubMedPubMedCentral

10.

Vogel AC, Gutmann DH, Morris SM (2017) Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol 59:1112–1116. https://doi.org/10.1111/dmcn.13526CrossRefPubMed

11.

Walsh KS, Velez JI, Kardel PG, Imas DM, Muenke M, Packer RJ, Castellanos FX, Acosta MT (2013) Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol 55:131–138. https://doi.org/10.1111/dmcn.12038CrossRefPubMed

12.

Cutting LE, Levine TM (2010) Cognitive profile of children with neurofibromatosis and reading disabilities. Child Neuropsychol 16:417–432. https://doi.org/10.1080/09297041003761985CrossRefPubMedPubMedCentral

13.

Hyman SL, Shores A, North KN (2005) The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037–1044. https://doi.org/10.1212/01.wnl.0000179303.72345.ceCrossRefPubMed

14.

Lidzba K, Granstrom S, Lindenau J, Mautner VF (2012) The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1. Dev Med Child Neurol 54:892–897. https://doi.org/10.1111/j.1469-8749.2012.04377.xCrossRefPubMed

15.

Eijk S, Mous SE, Dieleman GC, Dierckx B, Rietman AB, de Nijs PFA, Ten Hoopen LW, van Minkelen R, Elgersma Y, Catsman-Berrevoets CE, Oostenbrink R, Legerstee JS (2018) Autism spectrum disorder in an unselected cohort of children with neurofibromatosis type 1 (NF1). J Autism Dev Disord 48:2278–2285. https://doi.org/10.1007/s10803-018-3478-0CrossRefPubMedPubMedCentral

16.

Morris SM, Acosta MT, Garg S, Green J, Huson S, Legius E, North KN, Payne JM, Plasschaert E, Frazier TW, Weiss LA, Zhang Y, Gutmann DH, Constantino JN (2016) Disease burden and symptom structure of autism in neurofibromatosis type 1: a study of the international NF1-ASD consortium team (INFACT). JAMA Psychiatry 73:1276–1284. https://doi.org/10.1001/jamapsychiatry.2016.2600CrossRefPubMedPubMedCentral

17.

North KN, Riccardi V, Samango-Sprouse C, Ferner R, Moore B, Legius E, Ratner N, Denckla MB (1997) Cognitive function and academic performance in neurofibromatosis. 1: Consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 48:1121–1127. https://doi.org/10.1212/wnl.48.4.1121CrossRefPubMed

18.

Summers MA, Quinlan KG, Payne JM, Little DG, North KN, Schindeler A (2015) Skeletal muscle and motor deficits in neurofibromatosis type 1. J Musculoskelet Neuronal Interact 15:161–170PubMedPubMedCentral

19.

Garwood MM, Bernacki JM, Fine KM, Hainsworth KR, Davies WH, Klein-Tasman BP (2012) Physical, cognitive, and psychosocial predictors of functional disability and health-related quality of life in adolescents with neurofibromatosis-1. Pain Res Treat 2012:975364. https://doi.org/10.1155/2012/975364CrossRefPubMedPubMedCentral

20.

Payne JM, Haebich KM, MacKenzie R, Walsh KS, Hearps SJC, Coghill D, Barton B, Pride NA, Ullrich NJ, Tonsgard JH, Viskochil D, Schorry EK, Klesse L, Fisher MJ, Gutmann DH, Rosser T, Packer RJ, Korf B, Acosta MT, Bellgrove MA, North KN (2019) Cognition, ADHD symptoms, and functional impairment in children and adolescents with neurofibromatosis type 1. J Atten Disord:1087054719894384. https://doi.org/10.1177/1087054719894384

21.

Wolkenstein P, Rodriguez D, Ferkal S, Gravier H, Buret V, Algans N, Simeoni MC, Bastuji-Garin S (2009) Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases. Br J Dermatol 160:844–848. https://doi.org/10.1111/j.1365-2133.2008.08949.xCrossRefPubMed

22.

Wolters PL, Burns KM, Martin S, Baldwin A, Dombi E, Toledo-Tamula MA, Dudley WN, Gillespie A, Widemann BC (2015) Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A 167A:2103–2113. https://doi.org/10.1002/ajmg.a.37123CrossRefPubMed

23.

Diamond A (2013) Executive functions. Annu Rev Psychol 64:135–168. https://doi.org/10.1146/annurev-psych-113011-143750CrossRefPubMed

24.

Eby NS, Griffith JL, Gutmann DH, Morris SM (2019) Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging. Dev Med Child Neurol 61:972–978. https://doi.org/10.1111/dmcn.14144CrossRefPubMed

25.

Mautner VF, Granstrom S, Leark RA (2015) Impact of ADHD in adults with neurofibromatosis type 1: associated psychological and social problems. J Atten Disord 19:35–43. https://doi.org/10.1177/1087054712450749CrossRefPubMed

26.

Beaussart ML, Barbarot S, Mauger C, Roy A (2018) Systematic review and meta-analysis of executive functions in preschool and school-age children with neurofibromatosis type 1. J Int Neuropsychol Soc 24:977–994. https://doi.org/10.1017/S1355617718000383CrossRefPubMed

27.

Pievsky MA, McGrath RE (2018) The neurocognitive profile of attention-deficit/hyperactivity disorder: a review of meta-analyses. Arch Clin Neuropsychol 33:143–157. https://doi.org/10.1093/arclin/acx055CrossRefPubMed

28.

Demetriou EA, Lampit A, Quintana DS, Naismith SL, Song YJC, Pye JE, Hickie I, Guastella AJ (2018) Autism spectrum disorders: a meta-analysis of executive function. Mol Psychiatry 23:1198–1204. https://doi.org/10.1038/mp.2017.75CrossRefPubMed

29.

Lai CLE, Lau Z, Lui SSY, Lok E, Tam V, Chan Q, Cheng KM, Lam SM, Cheung EFC (2017) Meta-analysis of neuropsychological measures of executive functioning in children and adolescents with high-functioning autism spectrum disorder. Autism Res 10:911–939. https://doi.org/10.1002/aur.1723CrossRefPubMed

30.

Plasschaert E, Van Eylen L, Descheemaeker MJ, Noens I, Legius E, Steyaert J (2016) Executive functioning deficits in children with neurofibromatosis type 1: the influence of intellectual and social functioning. Am J Med Genet B Neuropsychiatr Genet 171B:348–362. https://doi.org/10.1002/ajmg.b.32414CrossRefPubMed

31.

Payne JM, Hyman SL, Shores EA, North KN (2011) Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behavior. Child Neuropsychol 17:313–329. https://doi.org/10.1080/09297049.2010.542746CrossRefPubMed

32.

Taddei M, Erbetta A, Esposito S, Saletti V, Bulgheroni S, Riva D (2019) Brain tumors in NF1 children: influence on neurocognitive and behavioral outcome. Cancers (Basel) 11. https://doi.org/10.3390/cancers11111772

33.

Casnar CL, Klein-Tasman BP (2017) Parent and teacher perspectives on emerging executive functioning in preschoolers with neurofibromatosis type 1: comparison to unaffected children and lab-based measures. J Pediatr Psychol 42:198–207. https://doi.org/10.1093/jpepsy/jsw042CrossRefPubMed

34.

Costa Dde S, de Paula JJ, de Rezende NA, Rodrigues LO, Malloy-Diniz LF, Romano-Silva MA, Miranda DM (2014) Neuropsychological impairments in elderly neurofibromatosis type 1 patients. Eur J Med Genet 57:216–219. https://doi.org/10.1016/j.ejmg.2014.02.004CrossRefPubMed

35.

Ibrahim AFA, Montojo CA, Haut KM, Karlsgodt KH, Hansen L, Congdon E, Rosser T, Bilder RM, Silva AJ, Bearden CE (2017) Spatial working memory in neurofibromatosis 1: altered neural activity and functional connectivity. Neuroimage Clin 15:801–811. https://doi.org/10.1016/j.nicl.2017.06.032CrossRefPubMedPubMedCentral

36.

Gilboa Y, Rosenblum S, Fattal-Valevski A, Toledano-Alhadef H, Josman N (2014) Is there a relationship between executive functions and academic success in children with neurofibromatosis type 1? Neuropsychol Rehabil 24:918–935. https://doi.org/10.1080/09602011.2014.920262CrossRefPubMed

37.

Arnold SS, Barton B, McArthur G, North KN, Payne JM (2016) Phonics training improves reading in children with neurofibromatosis type 1: a prospective intervention trial. J Pediatr 177:219–226 e212. https://doi.org/10.1016/j.jpeds.2016.06.037CrossRefPubMed

38.

Shilyansky C, Karlsgodt KH, Cummings DM, Sidiropoulou K, Hardt M, James AS, Ehninger D, Bearden CE, Poirazi P, Jentsch JD, Cannon TD, Levine MS, Silva AJ (2010) Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc Natl Acad Sci U S A 107:13141–13146. https://doi.org/10.1073/pnas.1004829107CrossRefPubMedPubMedCentral

39.

Yoncheva YN, Hardy KK, Lurie DJ, Somandepalli K, Yang L, Vezina G, Kadom N, Packer RJ, Milham MP, Castellanos FX, Acosta MT (2017) Computerized cognitive training for children with neurofibromatosis type 1: a pilot resting-state fMRI study. Psychiatry Res Neuroimaging 266:53–58. https://doi.org/10.1016/j.pscychresns.2017.06.003CrossRefPubMed

40.

Huijbregts S, Swaab H, de Sonneville L (2010) Cognitive and motor control in neurofibromatosis type I: influence of maturation and hyperactivity-inattention. Dev Neuropsychol 35:737–751. https://doi.org/10.1080/87565641.2010.508670CrossRefPubMed

41.

Koini M, Rombouts S, Veer IM, Van Buchem MA, Huijbregts SCJ (2017) White matter microstructure of patients with neurofibromatosis type 1 and its relation to inhibitory control. Brain Imaging Behav 11:1731–1740. https://doi.org/10.1007/s11682-016-9641-3CrossRefPubMed

42.

Pride NA, Korgaonkar MS, North KN, Barton B, Payne JM (2017) The neural basis of deficient response inhibition in children with neurofibromatosis type 1: evidence from a functional MRI study. Cortex 93:1–11. https://doi.org/10.1016/j.cortex.2017.04.022CrossRefPubMed

43.

Pride NA, Korgaonkar MS, North KN, Payne JM (2018) Impaired engagement of the ventral attention system in neurofibromatosis type 1. Brain Imaging Behav 12:499–508. https://doi.org/10.1007/s11682-017-9717-8CrossRefPubMed

44.

Ribeiro MJ, Violante IR, Bernardino I, Edden RA, Castelo-Branco M (2015) Abnormal relationship between GABA, neurophysiology and impulsive behavior in neurofibromatosis type 1. Cortex 64:194–208. https://doi.org/10.1016/j.cortex.2014.10.019CrossRefPubMed

45.

Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ (2002) Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415:526–530. https://doi.org/10.1038/nature711CrossRefPubMed

46.

Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH, Parada LF, Mody I, Silva AJ (2008) Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135:549–560. https://doi.org/10.1016/j.cell.2008.09.060CrossRefPubMedPubMedCentral

47.

Goncalves J, Violante IR, Sereno J, Leitao RA, Cai Y, Abrunhosa A, Silva AP, Silva AJ, Castelo-Branco M (2017) Testing the excitation/inhibition imbalance hypothesis in a mouse model of the autism spectrum disorder: in vivo neurospectroscopy and molecular evidence for regional phenotypes. Mol Autism 8:47. https://doi.org/10.1186/s13229-017-0166-4CrossRefPubMedPubMedCentral

48.

Robinson JE, Coughlin GM, Hori AM, Cho JR, Mackey ED, Turan Z, Patriarchi T, Tian L, Gradinaru V (2019) Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. Elife 8. https://doi.org/10.7554/eLife.48983

49.

Brown JA, Emnett RJ, White CR, Yuede CM, Conyers SB, O'Malley KL, Wozniak DF, Gutmann DH (2010) Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum Mol Genet 19:4515–4528. https://doi.org/10.1093/hmg/ddq382CrossRefPubMedPubMedCentral

50.

Diggs-Andrews KA, Gutmann DH (2013) Modeling cognitive dysfunction in neurofibromatosis-1. Trends Neurosci 36:237–247. https://doi.org/10.1016/j.tins.2012.12.002CrossRefPubMedPubMedCentral

51.

Roy A, Barbarot S, Roulin JL, Charbonnier V, Fasotti L, Stalder JF, Le Gall D (2014) Is executive function specifically impaired in children with neurofibromatosis type 1? A neuropsychological investigation of cognitive flexibility. Appl Neuropsychol Child 3:94–102. https://doi.org/10.1080/21622965.2012.704185CrossRefPubMed

52.

Rowe JB, Owen AM, Johnsrude IS, Passingham RE (2001) Imaging the mental components of a planning task. Neuropsychologia 39:315–327. https://doi.org/10.1016/s0028-3932(00)00109-3CrossRefPubMed

53.

Cornett KM, North KN, Rose KJ, Burns J (2015) Muscle weakness in children with neurofibromatosis type 1. Dev Med Child Neurol 57:733–736. https://doi.org/10.1111/dmcn.12777CrossRefPubMed

54.

Remigereau C, Roy A, Costini O, Barbarot S, Bru M, Le Gall D (2018) Praxis skills and executive function in children with neurofibromatosis type 1. Appl Neuropsychol Child 7:224–234. https://doi.org/10.1080/21622965.2017.1295856CrossRefPubMed

55.

Vassallo G, Mughal Z, Robinson L, Weisberg D, Roberts SA, Hupton E, Eelloo J, Burkitt Wright EM, Garg S, Lewis L, Evans DG, Stivaros SM (2020) Perceived fatigue in children and young adults with neurofibromatosis type 1. J Paediatr Child Health. https://doi.org/10.1111/jpc.14764

56.

Nitschke K, Kostering L, Finkel L, Weiller C, Kaller CP (2017) A meta-analysis on the neural basis of planning: activation likelihood estimation of functional brain imaging results in the Tower of London task. Hum Brain Mapp 38:396–413. https://doi.org/10.1002/hbm.23368CrossRefPubMed

57.

Faraone SV, Larsson H (2019) Genetics of attention deficit hyperactivity disorder. Mol Psychiatry 24:562–575. https://doi.org/10.1038/s41380-018-0070-0CrossRefPubMed

58.

Tick B, Bolton P, Happe F, Rutter M, Rijsdijk F (2016) Heritability of autism spectrum disorders: a meta-analysis of twin studies. J Child Psychol Psychiatry 57:585–595. https://doi.org/10.1111/jcpp.12499CrossRefPubMed

59.

Ghirardi L, Pettersson E, Taylor MJ, Freitag CM, Franke B, Asherson P, Larsson H, Kuja-Halkola R (2019) Genetic and environmental contribution to the overlap between ADHD and ASD trait dimensions in young adults: a twin study. Psychol Med 49:1713–1721. https://doi.org/10.1017/S003329171800243XCrossRefPubMed

60.

Pinto R, Rijsdijk F, Ronald A, Asherson P, Kuntsi J (2016) The genetic overlap of attention-deficit/hyperactivity disorder and autistic-like traits: an investigation of individual symptom scales and cognitive markers. J Abnorm Child Psychol 44:335–345. https://doi.org/10.1007/s10802-015-0037-4CrossRefPubMed

61.

Association AP (2013) Diagnostic and statistical manual of mental disorders, 5th edn Washington, DCCrossRef

62.

Barkley RA (1997) Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121:65–94. https://doi.org/10.1037/0033-2909.121.1.65CrossRefPubMed

63.

Mueller A, Hong DS, Shepard S, Moore T (2017) Linking ADHD to the neural circuitry of attention. Trends Cogn Sci 21:474–488. https://doi.org/10.1016/j.tics.2017.03.009CrossRefPubMedPubMedCentral

64.

Salum GA, Sonuga-Barke E, Sergeant J, Vandekerckhove J, Gadelha A, Moriyama TS, Graeff-Martins AS, Manfro GG, Polanczyk G, Rohde LA (2014) Mechanisms underpinning inattention and hyperactivity: neurocognitive support for ADHD dimensionality. Psychol Med 44:3189–3201. https://doi.org/10.1017/S0033291714000919CrossRefPubMed

65.

Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF (2005) Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 57:1336–1346. https://doi.org/10.1016/j.biopsych.2005.02.006CrossRefPubMed

66.

Isquith PK, Roth RM, Gioia G (2013) Contribution of rating scales to the assessment of executive functions. Appl Neuropsychol Child 2:125–132. https://doi.org/10.1080/21622965.2013.748389CrossRefPubMed

67.

Sagvolden T, Johansen EB, Aase H, Russell VA (2005) A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 28:397–419; discussion 419–368. https://doi.org/10.1017/S0140525X05000075CrossRefPubMed

68.

Sonuga-Barke EJ (2003) The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev 27:593–604. https://doi.org/10.1016/j.neubiorev.2003.08.005CrossRefPubMed

69.

Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, Castellanos FX (2012) Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am J Psychiatry 169:1038–1055. https://doi.org/10.1176/appi.ajp.2012.11101521CrossRefPubMed

70.

Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, Rohde LA, Sonuga-Barke EJ, Tannock R, Franke B (2015) Attention-deficit/hyperactivity disorder. Nat Rev Dis Prim 1:15020. https://doi.org/10.1038/nrdp.2015.20CrossRefPubMed

71.

Maddox BB, Cleary P, Kuschner ES, Miller JS, Armour AC, Guy L, Kenworthy L, Schultz RT, Yerys BE (2018) Lagging skills contribute to challenging behaviors in children with autism spectrum disorder without intellectual disability. Autism 22:898–906. https://doi.org/10.1177/1362361317712651CrossRefPubMed

72.

Rosello B, Berenguer C, Baixauli I, Colomer C, Miranda A (2018) ADHD symptoms and learning behaviors in children with ASD without intellectual disability. A mediation analysis of executive functions. PLoS One 13:e0207286. https://doi.org/10.1371/journal.pone.0207286CrossRefPubMedPubMedCentral

73.

de Vries M, Geurts H (2015) Influence of autism traits and executive functioning on quality of life in children with an autism spectrum disorder. J Autism Dev Disord 45:2734–2743. https://doi.org/10.1007/s10803-015-2438-1CrossRefPubMedPubMedCentral

74.

Leung RC, Vogan VM, Powell TL, Anagnostou E, Taylor MJ (2016) The role of executive functions in social impairment in autism spectrum disorder. Child Neuropsychol 22:336–344. https://doi.org/10.1080/09297049.2015.1005066CrossRefPubMed

75.

Mostert-Kerckhoffs MA, Staal WG, Houben RH, de Jonge MV (2015) Stop and change: inhibition and flexibility skills are related to repetitive behavior in children and young adults with autism spectrum disorders. J Autism Dev Disord 45:3148–3158. https://doi.org/10.1007/s10803-015-2473-yCrossRefPubMedPubMedCentral

76.

Pellicano E (2007) Links between theory of mind and executive function in young children with autism: clues to developmental primacy. Dev Psychol 43:974–990. https://doi.org/10.1037/0012-1649.43.4.974CrossRefPubMed

77.

Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, Szatmari P, Ameis SH (2019) Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry 6:819–829. https://doi.org/10.1016/S2215-0366(19)30289-5CrossRefPubMed

78.

Di Martino A, Yan CG, Li Q, Denio E, Castellanos FX, Alaerts K, Anderson JS, Assaf M, Bookheimer SY, Dapretto M, Deen B, Delmonte S, Dinstein I, Ertl-Wagner B, Fair DA, Gallagher L, Kennedy DP, Keown CL, Keysers C, Lainhart JE, Lord C, Luna B, Menon V, Minshew NJ, Monk CS, Mueller S, Muller RA, Nebel MB, Nigg JT, O'Hearn K, Pelphrey KA, Peltier SJ, Rudie JD, Sunaert S, Thioux M, Tyszka JM, Uddin LQ, Verhoeven JS, Wenderoth N, Wiggins JL, Mostofsky SH, Milham MP (2014) The autism brain imaging data exchange: towards a large-scale evaluation of the intrinsic brain architecture in autism. Mol Psychiatry 19:659–667. https://doi.org/10.1038/mp.2013.78CrossRefPubMed

79.

Muhle RA, Reed HE, Stratigos KA, Veenstra-VanderWeele J (2018) The emerging clinical neuroscience of autism spectrum disorder: a review. JAMA Psychiatry 75:514–523. https://doi.org/10.1001/jamapsychiatry.2017.4685CrossRefPubMed

80.

Holiga S, Hipp JF, Chatham CH, Garces P, Spooren W, D'Ardhuy XL, Bertolino A, Bouquet C, Buitelaar JK, Bours C, Rausch A, Oldehinkel M, Bouvard M, Amestoy A, Caralp M, Gueguen S, Ly-Le Moal M, Houenou J, Beckmann CF, Loth E, Murphy D, Charman T, Tillmann J, Laidi C, Delorme R, Beggiato A, Gaman A, Scheid I, Leboyer M, d'Albis MA, Sevigny J, Czech C, Bolognani F, Honey GD, Dukart J (2019) Patients with autism spectrum disorders display reproducible functional connectivity alterations. Sci Transl Med 11. https://doi.org/10.1126/scitranslmed.aat9223

81.

Yerys BE, Tunc B, Satterthwaite TD, Antezana L, Mosner MG, Bertollo JR, Guy L, Schultz RT, Herrington JD (2019) Functional connectivity of frontoparietal and salience/ventral attention networks have independent associations with co-occurring attention-deficit/hyperactivity disorder symptoms in children with autism. Biol Psychiatry Cogn Neurosci Neuroimaging 4:343–351. https://doi.org/10.1016/j.bpsc.2018.12.012CrossRefPubMedPubMedCentral

82.

Pride NA, Crawford H, Payne JM, North KN (2013) Social functioning in adults with neurofibromatosis type 1. Res Dev Disabil 34:3393–3399. https://doi.org/10.1016/j.ridd.2013.07.011CrossRefPubMed

83.

Koth CW, Cutting LE, Denckla MB (2000) The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol 6:185–194. https://doi.org/10.1076/chin.6.3.185.3155CrossRefPubMed

84.

Lehtonen A, Howie E, Trump D, Huson SM (2013) Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol 55:111–125. https://doi.org/10.1111/j.1469-8749.2012.04399.xCrossRefPubMed

85.

Payne JM, Arnold SS, Pride NA, North KN (2012) Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1? Dev Med Child Neurol 54:898–904. https://doi.org/10.1111/j.1469-8749.2012.04357.xCrossRefPubMed

86.

Fry AF, Hale S (2000) Relationships among processing speed, working memory, and fluid intelligence in children. Biol Psychol 54:1–34. https://doi.org/10.1016/s0301-0511(00)00051-xCrossRefPubMed

87.

Gathercole SE (1999) Cognitive approaches to the development of short-term memory. Trends Cogn Sci 3:410–419. https://doi.org/10.1016/s1364-6613(99)01388-1CrossRefPubMed

88.

Rennie B, Beebe-Frankenberger M, Swanson HL (2014) A longitudinal study of neuropsychological functioning and academic achievement in children with and without signs of attention-deficit/hyperactivity disorder. J Clin Exp Neuropsychol 36:621–635. https://doi.org/10.1080/13803395.2014.921284CrossRefPubMed

89.

Swanson HL, Howard CB, Saez L (2006) Do different components of working memory underlie different subgroups of reading disabilities? J Learn Disabil 39:252–269. https://doi.org/10.1177/00222194060390030501CrossRefPubMed

90.

Zheng X, Swanson HL, Marcoulides GA (2011) Working memory components as predictors of children's mathematical word problem solving. J Exp Child Psychol 110:481–498. https://doi.org/10.1016/j.jecp.2011.06.001CrossRefPubMed

91.

Hardy KK (2020) Efficacy of computerized cognitive training and stimulant medication in neurofibromatosis type 1 (COGTRAIN). https://clinicaltrials.gov/ct2/show/NCT02944032

92.

Garg S, Lehtonen A, Huson SM, Emsley R, Trump D, Evans DG, Green J (2013) Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol 55:139–145. https://doi.org/10.1111/dmcn.12043CrossRefPubMed

93.

Hartman CA, Geurts HM, Franke B, Buitelaar JK, Rommelse NNJ (2016) Changing ASD-ADHD symptom co-occurrence across the lifespan with adolescence as crucial time window: illustrating the need to go beyond childhood. Neurosci Biobehav Rev 71:529–541. https://doi.org/10.1016/j.neubiorev.2016.09.003CrossRefPubMed

94.

Maloney SE, Chandler KC, Anastasaki C, Rieger MA, Gutmann DH, Dougherty JD (2018) Characterization of early communicative behavior in mouse models of neurofibromatosis type 1. Autism Res 11:44–58. https://doi.org/10.1002/aur.1853CrossRefPubMed

95.

Gioia GA, Isquith PK, Kenworthy L, Barton RM (2002) Profiles of everyday executive function in acquired and developmental disorders. Child Neuropsychol 8:121–137. https://doi.org/10.1076/chin.8.2.121.8727CrossRefPubMed

96.

Rosenthal M, Wallace GL, Lawson R, Wills MC, Dixon E, Yerys BE, Kenworthy L (2013) Impairments in real-world executive function increase from childhood to adolescence in autism spectrum disorders. Neuropsychology 27:13–18. https://doi.org/10.1037/a0031299CrossRefPubMedPubMedCentral

97.

Lawson RA, Papadakis AA, Higginson CI, Barnett JE, Wills MC, Strang JF, Wallace GL, Kenworthy L (2015) Everyday executive function impairments predict comorbid psychopathology in autism spectrum and attention deficit hyperactivity disorders. Neuropsychology 29:445–453. https://doi.org/10.1037/neu0000145CrossRefPubMed

98.

Wilson CG, Nusbaum AT, Whitney P, Hinson JM (2018) Trait anxiety impairs cognitive flexibility when overcoming a task acquired response and a preexisting bias. PLoS One 13:e0204694. https://doi.org/10.1371/journal.pone.0204694CrossRefPubMedPubMedCentral

99.

Burrows CA, Timpano KR, Uddin LQ (2017) Putative brain networks underlying repetitive negative thinking and comorbid internalizing problems in autism. Clin Psychol Sci 5:522–536. https://doi.org/10.1177/2167702616683506CrossRefPubMedPubMedCentral

100.

Schoemaker K, Mulder H, Dekovic M, Matthys W (2013) Executive functions in preschool children with externalizing behavior problems: a meta-analysis. J Abnorm Child Psychol 41:457–471. https://doi.org/10.1007/s10802-012-9684-xCrossRefPubMed

101.

Sosic-Vasic Z, Kroner J, Schneider S, Vasic N, Spitzer M, Streb J (2017) The association between parenting behavior and executive functioning in children and young adolescents. Front Psychol 8:472. https://doi.org/10.3389/fpsyg.2017.00472CrossRefPubMedPubMedCentral

102.

Sanislow CA, Ferrante M, Pacheco J, Rudorfer MV, Morris SE (2019) Advancing translational research using NIMH research domain criteria and computational methods. Neuron 101:779–782. https://doi.org/10.1016/j.neuron.2019.02.024CrossRefPubMed

103.

Walsh KS, Janusz J, Wolters PL, Martin S, Klein-Tasman BP, Toledo-Tamula MA, Thompson HL, Payne JM, Hardy KK, de Blank P, Semerjian C, Gray LS, Solomon SE, Ullrich N, Collaboration REI (2016) Neurocognitive outcomes in neurofibromatosis clinical trials: recommendations for the domain of attention. Neurology 87:S21–S30. https://doi.org/10.1212/WNL.0000000000002928CrossRefPubMedPubMedCentral

104.

Payne JM, Hearps SJC, Walsh KS, Paltin I, Barton B, Ullrich NJ, Haebich KM, Coghill D, Gioia GA, Cantor A, Cutter G, Tonsgard JH, Viskochil D, Rey-Casserly C, Schorry EK, Ackerson JD, Klesse L, Fisher MJ, Gutmann DH, Rosser T, Packer RJ, Korf B, Acosta MT, North KN, Consortium NFCT (2019) Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Ann Clin Transl Neurol 6:2555–2565. https://doi.org/10.1002/acn3.50952CrossRefPubMedPubMedCentral

105.

Vaidya CJ, You X, Mostofsky S, Pereira F, Berl MM, Kenworthy L (2020) Data-driven identification of subtypes of executive function across typical development, attention deficit hyperactivity disorder, and autism spectrum disorders. J Child Psychol Psychiatry 61:51–61. https://doi.org/10.1111/jcpp.13114CrossRefPubMed

106.

Sanders SJ, Sahin M, Hostyk J, Thurm A, Jacquemont S, Avillach P, Douard E, Martin CL, Modi ME, Moreno-De-Luca A, Raznahan A, Anticevic A, Dolmetsch R, Feng G, Geschwind DH, Glahn DC, Goldstein DB, Ledbetter DH, Mulle JG, Pasca SP, Samaco R, Sebat J, Pariser A, Lehner T, Gur RE, Bearden CE (2019) A framework for the investigation of rare genetic disorders in neuropsychiatry. Nat Med 25:1477–1487. https://doi.org/10.1038/s41591-019-0581-5CrossRefPubMed

107.

Chabernaud C, Mennes M, Kardel PG, Gaillard WD, Kalbfleisch ML, Vanmeter JW, Packer RJ, Milham MP, Castellanos FX, Acosta MT (2012) Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1. Neurosci Lett 515:28–33. https://doi.org/10.1016/j.neulet.2012.03.009CrossRefPubMedPubMedCentral

108.

Shofty B, Bergmann E, Zur G, Asleh J, Bosak N, Kavushansky A, Castellanos FX, Ben-Sira L, Packer RJ, Vezina GL, Constantini S, Acosta MT, Kahn I (2019) Autism-associated Nf1 deficiency disrupts corticocortical and corticostriatal functional connectivity in human and mouse. Neurobiol Dis 130:104479. https://doi.org/10.1016/j.nbd.2019.104479CrossRefPubMedPubMedCentral

Titel: An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains
verfasst von: Taylor F. Smith
Jessica A. Kaczorowski
Maria T. Acosta
Publikationsdatum: 03.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Child's Nervous System / Ausgabe 10/2020
Print ISSN: 0256-7040
Elektronische ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-020-04745-w

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

10.04.2024 | Narbenhernie | Nachrichten

Deutlich weniger Narbenhernien mit der Small-Bites-Technik

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Visual function tests including the role of optical coherence tomography in neurofibromatosis 1

Jim Tait Goodrich

Surgical management of peripheral nerve sheath tumours in children, with special consideration of neurofibromatoses

Neurofibromatosis type 1–related hydrocephalus: causes and treatment considerations

Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease

Spinal manifestations of Neurofibromatosis type 1

Neu im Fachgebiet Chirurgie

Hochrisiko-Eingriffe für postoperative Übelkeit

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Deutlich weniger Narbenhernien mit der Small-Bites-Technik

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“